SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for...
Hence then, the article about yoltech therapeutics announces fda clearance of investigational new drug ind application for yolt 101 an in vivo base editing therapy to treat heterozygous familial hypercholesterolemia hefh was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH) )
Also on site :
- Lauren Chapin, the Youngest Kid on ‘Father Knows Best,’ Dies at 80
- Wynn Resorts faces second lawsuit after data breach incident involving employees
- Nancy Guthrie Update: Mexican Mothers Face Hurdles Joining Search